Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
Public ClinicalTrials.gov record NCT01064401. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting multiple sclerosis. The secondary study objectives are to test the superiority of DAC HYP compared to IFN β-1a in slowing functional decline and disability progression and maintaining quality of life in this participant population.
Study identification
- NCT ID
- NCT01064401
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,841 participants
Conditions and interventions
Conditions
Interventions
- BIIB019 (Daclizumab High Yield Process) Biological
- Interferon beta-1a Placebo Drug
- Interferon beta-1a Biological
- Daclizumab High Yield Process Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2010 (Type not available)
- Primary completion
- Mar 2014 (Actual)
- Completion
- Jul 2014 (Actual)
- Last update posted
- Jul 11, 2016
2010 – 2014
United States locations
- U.S. sites
- 46
- U.S. states
- 28
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Gilbert | Arizona | — | — |
| Research Site | Phoenix | Arizona | — | — |
| Research Site | Tucson | Arizona | — | — |
| Research Site | Little Rock | Arkansas | — | — |
| Research Site | La Jolla | California | — | — |
| Research Site | Aurora | Colorado | — | — |
| Research Site | Naples | Florida | — | — |
| Research Site | Pompano Beach | Florida | — | — |
| Research Site | St. Petersburg | Florida | — | — |
| Research Site | Sunrise | Florida | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Evanston | Illinois | — | — |
| Research Site | Fort Wayne | Indiana | — | — |
| Research Site | Indianapolis | Indiana | — | — |
| Research Site | Des Moines | Iowa | — | — |
| Research Site | Kansas City | Kansas | — | — |
| Research Site | Lexington | Kentucky | — | — |
| Research Site | Baltimore | Maryland | — | — |
| Research Site | Springfield | Massachusetts | — | — |
| Research Site | Worchester | Massachusetts | — | — |
| Research Site | Clinton Township | Michigan | — | — |
| Research Site | St Louis | Missouri | — | — |
| Research Site | Lebanon | New Hampshire | — | — |
| Research Site | New Brunswick | New Jersey | — | — |
| Research Site | Albuquerque | New Mexico | — | — |
| Research Site | Buffalo | New York | — | — |
| Research Site | Latham | New York | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Rochester | New York | — | — |
| Research Site | Charlotte | North Carolina | — | — |
| Research Site | Raleigh | North Carolina | — | — |
| Research Site | Winston-Salem | North Carolina | — | — |
| Research Site | Medford | Oregon | — | — |
| Research Site | Portland | Oregon | — | — |
| Research Site | Allentown | Pennsylvania | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Pittsburgh | Pennsylvania | — | — |
| Research Site | Providence | Rhode Island | — | — |
| Research Site | Franklin | Tennessee | — | — |
| Research Site | Knoxville | Tennessee | — | — |
| Research Site | Salt Lake City | Utah | — | — |
| Research Site | Burlington | Vermont | — | — |
| Research Site | Kirkland | Washington | — | — |
| Research Site | Seattle | Washington | — | — |
| Research Site | Tacoma | Washington | — | — |
| Research Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 182 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01064401, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2016 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01064401 live on ClinicalTrials.gov.